RxDoctor Payments Data

Amit Kumar, MD

Cardiovascular Disease · Dyer, INNPI 1336197573

Payments from drug & device makers

$10,613in general payments, 2019–2025

Across 458 payments — averaging $23.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Novartis$1K
  • Actelion Pharmaceuticals US, Inc.$653
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$610
  • Boston Scientific$590
  • Johnson & Johnson$554
  • plus $6K from 43 others

What the payments were for

  • Speaking & faculty fees$1852%
  • Food & beverage$10,33397%
  • Education$951%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,613 in reported general payments places this provider in the 70th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$304,418
Medicare patients
1,385
Services billed
3,468

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis13$520,785
EliquisApixaban230$242,420
EntrestoSacubitril/Valsartan121$160,952
JardianceEmpagliflozin108$83,681
FarxigaDapagliflozin Propanediol76$64,737
XareltoRivaroxaban50$54,645
Repatha SureclickEvolocumab69$42,557
BrilintaTicagrelor19$20,275
Varenicline Tartrate29$6,875
Atorvastatin Calcium432$5,076
Metoprolol Succinate283$4,285
Ranolazine ErRanolazine29$3,387
ClopidogrelClopidogrel Bisulfate228$2,221
Amlodipine Besylate182$1,793
Losartan Potassium150$1,611

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$331$763,205243 claims
NovartisEntresto$1,057$160,952121 claims
AstraZenecaFarxiga, Brilinta$386$85,01195 claims
Boehringer IngelheimJardiance$535$83,681108 claims
Johnson & JohnsonXarelto$554$54,64550 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Dyer

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →